TY - JOUR
T1 - Use of subcutaneous ivermectin in hyperinfection syndrome by Strongyloides stercoralis. A case report / Uso de ivermectina subcutánea en síndrome de hiperinfección por Strongyloides stercoralis. Reporte un caso
AU - Hennessey, Diana Carolina
AU - Ballesteros, Oscar Andrés
AU - Merchán, Diego Javier
AU - Guevara, Freddy Orlando
AU - Severiche, Diego Fernando
PY - 2020/6/15
Y1 - 2020/6/15
N2 - Strongyloidiasis is a disease caused by the nematode Strongyloides stercoralis that is endemic in rural regions in tropical and subtropical countries. Immunosuppressed patients have an increased risk of infection by this parasitic and are at risk of developing a hyperinfection syndrome which carries a higher risk of death. However, in Colombia and the world there is no parenteral presentation of ivermectin for the use in humans, which is an important problem in patients who have compromised enteral absorption, as in the case of patients with intestinal obstructions. We present the first case of hyperinfection syndrome by Strongyloides stercoralis in Colombia treated with subcutaneous ivermectin in order to encourage pharmacokinetic and pharmacodynamic studies to establish this route of administration in the future as an alternative to those patients who have a high risk of therapeutic failure with the oral route. © 2019, Instituto Nacional de Salud.
AB - Strongyloidiasis is a disease caused by the nematode Strongyloides stercoralis that is endemic in rural regions in tropical and subtropical countries. Immunosuppressed patients have an increased risk of infection by this parasitic and are at risk of developing a hyperinfection syndrome which carries a higher risk of death. However, in Colombia and the world there is no parenteral presentation of ivermectin for the use in humans, which is an important problem in patients who have compromised enteral absorption, as in the case of patients with intestinal obstructions. We present the first case of hyperinfection syndrome by Strongyloides stercoralis in Colombia treated with subcutaneous ivermectin in order to encourage pharmacokinetic and pharmacodynamic studies to establish this route of administration in the future as an alternative to those patients who have a high risk of therapeutic failure with the oral route. © 2019, Instituto Nacional de Salud.
UR - http://www.scopus.com/inward/record.url?scp=85083219350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083219350&partnerID=8YFLogxK
M3 - Artículo de Investigación
AN - SCOPUS:85083219350
SN - 0120-4157
VL - 40
JO - Biomedica
JF - Biomedica
IS - 2
M1 - 6098
ER -